Inovio Pharmaceuticals (INO) Total Non-Current Liabilities (2010 - 2022)

Inovio Pharmaceuticals has reported Total Non-Current Liabilities for 13 years, with the latest figure at $126.2 million in Q4 2022.

• Quarterly Total Non-Current Liabilities rose 31.08% year-over-year to $126.2 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $126.2 million (up 31.08% YoY) and the FY2022 annual result came in at $126.2 million, up 31.08% from the prior year.
• Total Non-Current Liabilities improved to $126.2 million in Q4 2022 per INO's latest filing, from $124.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $161.7 million in Q2 2022 and troughed at $37.0 million in Q3 2018.
• A 5-year average of $96.7 million and a median of $102.4 million in 2019 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2019 and 2021: Total Non-Current Liabilities surged 199.86% in 2019, then slumped 43.27% in 2021.
• Over 5 years, Total Non-Current Liabilities stood at $44.0 million in 2018, then soared by 194.88% to $129.7 million in 2019, then slumped by 39.43% to $78.6 million in 2020, then gained by 22.51% to $96.3 million in 2021, then surged by 31.08% to $126.2 million in 2022.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $126.2 million, $124.6 million, and $161.7 million for Q4 2022, Q3 2022, and Q2 2022 respectively.